Transdisciplinary approach to managing hepatitis c virus infection in patients at a tertiary care cancer center

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 9, 2016, Pages 1185-1188

  Torres, Harrys A ^a   Roach, Lillian R ^a   Mahale, Parag ^a   Economides, Minas P ^a   Blechacz, Boris ^a   Miller, Ethan ^a   Borchardt, Roy ^a   Rashid, Anis ^a   Oo, Thein H ^a   Shukla, Bhavarth ^a   Farida, Malik ^a   Ericsson, Charles D ^b   Granwehr, Bruno P ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CENTER; CANCER PATIENT; HEPATITIS C; HUMAN; INTERDISCIPLINARY COMMUNICATION; INTERDISCIPLINARY EDUCATION; PATIENT CARE; STAFF TRAINING; TEAMWORK; TERTIARY HEALTH CARE; UNITED STATES; DRUG EFFECTS; HEPACIVIRUS; NEOPLASM; VIROLOGY;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; NEOPLASMS; TERTIARY HEALTHCARE;

EID: 84985906392     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0125     Document Type: Article

References (14)

1. AASLD/IDSA/IAS-USA. Recommendations for testing, managing and treating hepatitis C. Available at http://www.hcvguidelines.org. Accessed February 26 2016.
2. Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 2015; 13:41-50.
3. Torres HA, Adachi JA, Roach LR, et al. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis 2012; 54:740-742.
4. Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leuk lymphoma 1995; 17:245-249.
5. Torres HA, Kaseb A, Mahale P, et al. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocellular Carcinoma 2014; 1:109-114.
6. Mahale P, Kontoyiannis D P, Chemaly R F, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012; 57:1177-1185.
7. Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 2014; 20:2771-2776.
8. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas: epidemiology, molecular signature and clinical management. J Hepatol 2013; 59:169-177.
9. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014; 25:1404-1410.
10. Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 2016; 22:717-722.
11. Klingemann HG, Grigg A P, Wilkie-Boyd K, et al. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991; 78:3306-3311.
12. Torres HA, McDonald GB. How we treat hepatitis C virus infection in patients with hematologic malignancies [published online ahead of print]. Blood, pii: blood-2016-05-718643.
13. Torres HA, Chong P P, De Lima M, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant 2015; 21:1870-1882.
14. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364:2199-2207.